Aclaris Therapeutics ACRS Fair Value Of Warrants Issued In Connection With In License Agreement

Fair Value Of Warrants Issued In Connection With In License Agreement at other companies

Inhibrx Biosciences, Inc.INBX

$430K—

Candel Therapeutics, Inc.CADL

$519.75K—

PowerFleet, Inc.AIOT

$0—

Riot Platforms, Inc.RIOT

$51.85M+224%

KEE

Keel Infrastructure Corp. Common StockKEEL

$2.15M—

OppFiOPFI

-$21.3M-199%

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept acrs:FairValueOfWarrantsIssuedInConnectionWithInLicenseAgreement.

The official record: Aclaris Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's fair value of warrants issued in connection with in license agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's fair value of warrants issued in connection with in license agreement?: Aclaris Therapeutics (ACRS) reported fair value of warrants issued in connection with in license agreement of $11.21M in Q4 2024.
What does fair value of warrants issued in connection with in license agreement mean?: This represents the non-cash valuation of warrants granted as part of an in-licensing agreement or strategic partnership. It reflects the cost of securing access to external intellectual property through equity-linked instruments rather than immediate cash payments. This provides insight into the company's use of dilutive financing to support its pipeline development.